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SAPIEN® transcatheter implantation therapy versus drug treatment with or 
without aortic balloon valvoplasty. The outcomes used were effectiveness (as 
measured by clinical outcomes chance of successful implantation procedure and 
survival) and safety. The results were expressed as the reason of incremental 
cost-effectiveness ratio (ICER) per years saved and years free from serious 
adverse events. Probabilistic sensitivity analysis was performed on the main 
parameters of the model. RESULTS: Compared with medical therapy with or 
without aortic balloon valvuloplasty, the employment of the SAPIEN® valve 
presents safety in the procedure, increased survival and compatible ICER – US$ 
40.000/life of year saved. CONCLUSIONS: The use of SAPIEN® transcatheter 
implantation results in improved survival and functional improvement in 
patients with low risk of serious adverse events, and demonstrates a cost-
effectiveness profile when compared to other technologies already incorporated 
by the Brazilian public health system.  
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OBJECTIVES: To evaluate the cost-effectiveness of apixaban compared to 
enoxaparin, rivaroxaban and dabigatran in venous thromboembolism prevention 
(VTEp) in patients undergoing elective total knee or hip replacement (TKR, THR) 
from the private payer’s perspective in Colombia. METHODS: An economic 
model, including both a decision tree component and a Markov model was 
created to compare apixaban 5mg/day, enoxaparin 40mg/day, dabigatran 
220mg/day and rivaroxaban 10mg/day. The decision tree considers potential 
VTE, bleeding, death events as well as no-events which occur over the short-
term and lends itself to model the prophylactic and post-prophylactic phases 
over the first 90 days post-surgery. Events that occur over the long term are 
modeled using a Markov structure, which provides the option to simulate events 
such as recurrent VTE and post-thrombotic syndrome. The model relies upon the 
results from a mixed treatment comparison study for key efficacy and safety 
inputs, information from published literature for unit cost and utility data, and 
Colombian cost and patterns of care study for resource use and event costs. 
Results are reported as cost per quality-adjusted life years gained (QALY’s) and 
life years gained (LYG) over a prophylaxis + five-year time horizon. A discount 
rate of 3.5% was used for both costs and outcomes. RESULTS: Results indicate 
that the use of apixaban is dominant compared to enoxaparin and dabigatran in 
the overall population for THR and TKR (less number of VTE events, total bleeds 
and deaths which generated higher number QALYs and lower overall costs). 
When compared to rivaroxaban the model results show similar long-term gains 
in QALY’s and LYG for apixaban, as well as similar costs -showing small savings 
for apixaban mainly due to lower bleeding costs. CONCLUSIONS: Apixaban is a 
cost-effective alternative in preventing VTE in patients undergoing THR or TKR 
in Colombian private setting.  
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OBJECTIVES: Most patients with myocardial infarction in Colombia are treated 
with streptokynase, despite tenecteplase being recognized as more effective. Our 
objective was to evaluate the cost-effectiveness and cost-utility of tenecteplase, 
compared with streptokinase, in the treatment of ST elevation myocardial 
infarction. METHODS: We designed a decision tree model, from the perspective 
of the Colombian health system. We calculated quality adjusted life years (QALY) 
gained (using data Tuft's registry), as well as cost per death, and cost per major 
outcome averted (death, stroke, severe heart failure). The costs were estimated 
in Colombian pesos for 2012 (Exchange rate 1US$=COP$1785) using national tariff 
manuals (Social Security 2001 with inflation adjustment) and resource use 
obtained from our local university hospital, validated by national expert panel. 
We performed a probabilistic and deterministic sensitivity analysis. RESULTS: 
The average total cost for a tenecteplase treated patient was US$1456. The cost 
per incremental QALY gained with tenecteplase was US$14,447; US$95,302 per 
death averted, and US$38,578 for major outcome averted. The average total cost 
for the treatment of acute phase of all myocardial infarctions for 2012 was 
estimated in US$728,000. Monte Carlo simulation acceptability curve showed 
that in 85% of the trials the result would be cost-effective, assuming a 
willingness to pay of up to three times the per capita gross domestic product 
(Colombia's per capita GDP is US$6723). If the cost of tenecteplase were lowered 
from US$2066 to US$389 the cost per QALY would reach the one per capita GDP 
threshold. CONCLUSIONS: Our results suggest that tenecteplase is cost effective 
if we accept the three-times per capita GDP threshold.  
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OBJECTIVES: The multi-centered, double-blind, randomized PLATO trial on 18,624 
patients from 43 countries has demonstrated that ticagrelor was superior in 
reducing the rates of cardiovascular mortality, myocardial infarction (MI), or stroke 
among patients with acute coronary syndrome (ACS) compared to clopidogrel but 
without a significant increase in major bleedings. This study aimed to evaluate the 
long-term cost-effectiveness of ticagrelor plus acetylsalicylic acid (ASA) versus 
clopidogrel plus ASA in ACS patients in Hong Kong (HK) from a public hospital’s 
perspective. METHODS: A two-phase state-transition Markov model was developed 
to estimate the long-term economic and health outcomes measured as quality-
adjusted life years (QALYs). PLATO data were utilized to estimate patients’ resource 
use (incl. hospitalization bed days, investigations, interventions and blood products), 
rate of cardiovascular events (i.e. MI and stroke) and QALYs for the first year. 
Outcomes from the second year onwards were extrapolated using results from the 
first year. Direct health care costs were HK-specific and utility data were adopted 
from published literature. Time horizons were set at 1 year, 5 years and patients’ 
lifetime. All costs which were presented as 2012 figures and effectiveness were both 
discounted at 3% per annum. A series of one-way and multi-way sensitivity 
analyses were performed to test model robustness. RESULTS: Over a lifetime 
horizon, the use of ticagrelor led to improved clinical outcome with a discounted 
survival of 13.08 QALYs per patient in the ticagrelor treatment group compared to 
12.91 in the clopidogrel treatment group. Despite its higher daily cost, ticagrelor was 
predicted to significantly reduce resource utilization by HKD6,348 (USD814, 
1USD=7.8HKD) and stroke treatment cost by HKD45,226 (USD5,798) per patient 
which can be translated into a heavy public health care expenditure. 
CONCLUSIONS: The treatment of ACS patients with lifetime use of ticagrelor is 
considered cost-saving compared with clopidogrel from a public health care 
provider perspective in HK.  
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease 
characterized by uncoordinated atrial activation involving a rapid and irregular 
heartbeat. Its prevalence has been increasing worldwide. Antiarrhythmic drug 
therapy is a commonly-used treatment for paroxysmal AF, and catheter ablation 
has become an important treatment alternative. The purpose of this study was 
to assess the cost-effectiveness of catheter ablation compared to antiarrhythmic 
drug (AAD) therapy for the treatment of paroxysmal AF in Canada. METHODS: A 
simulation model was developed for a hypothetical cohort of 55-year-old 
patients with drug-refractory paroxysmal AF and a low stroke risk. The first year 
was modeled with a decision tree. Years 2 and beyond were modeled with a 
Markov simulation. The model treatment arms were catheter ablation and AAD 
mono-therapy. The model was created to assess costs and quality-adjusted life-
years over a lifetime horizon. Clinical efficacy of catheter ablation and AAD 
therapy were modeled based on the results of a recently-published randomized 
controlled trial (Wilber et al., 2010). Utilities and state transition probabilities 
were drawn from the published literature. Costs were specific to Canada. 
RESULTS: The incremental cost-effectiveness ratio for catheter ablation versus 
AAD therapy ranged from CAD$10,000 to a dominant strategy (cost less and is 
more effective) per quality-adjusted life-year. Over a lifetime horizon, the 
quality-adjusted life expectancy ranged from 11.25 to 11.75 years for catheter 
ablation compared to 10.75 to 11.25 years for AAD therapy. The results were 
robust in sensitivity analysis. Results were most sensitive to ablation costs, 
probability of successful ablation treatment, and probability of revision to AF. 
CONCLUSIONS: Catheter ablation appears to be cost-effective compared to AAD 
therapy among patients who had drug refractory paroxysmal AF in the Canadian 
population when using a cost-effectiveness threshold of CAD$50,000. Further 
research is necessary to understand the effect of newly approved OAC therapies. 
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OBJECTIVES: To evaluate the cost-effectiveness of new oral anticoagulants 
(apixaban, dabigatran and rivaroxaban) compared relative to each other and 
relative to warfarin for stroke prevention in patients with atrial fibrillation. 
METHODS: We developed a decision analytic model, designed as a probabilistic 
Markov model containing 200 different probability distributions. The model 
included eight health states; atrial fibrillation (AF), heart failure, moderate stroke 
sequela, severe stroke sequela, atrial fibrillation with previous AMI, atrial 
fibrillation with previous stroke, atrial fibrillation with major gastrointestinal 
bleeding and dead. Efficacy data was collected from a recently published report 
from the Canadian Health Technology Assessment Agency (CADTH). 
Epidemiological input data was gathered from registries. Data on Quality of Life 
were based on published EQ-5D data and costs were mainly based on national 
tariffs. The analysis was stratified according to risk of stroke as measured by 
CHA2DS2-VASc and risk of bleeding as measured by HAS-BLED. RESULTS: When 
the new drugs were compared relative to each other for medium risk patients, 
simulations indicated a 41% probability that apixaban is cost-effective, with 34% 
and 24% for dabigatran and rivaroxaban, respectively. For high risk patients, 
simulations indicated a 56% probability that dabigatran is cost-effective, with 
29% and 15% for apixaban and rivaroxaban, respectively. When comparing each 
of the new anticoagulants with the old (warfarin), analyses indicate a probability 
between 21% and 60% that warfarin is still cost-effective. In separate analyses, 
